Literature DB >> 12709314

Prevention of human rhinovirus infection by multivalent fab molecules directed against ICAM-1.

Catherine H Charles1, Guang X Luo, Lori A Kohlstaedt, Ianessa G Morantte, Elliott Gorfain, Linguang Cao, Jimmy H Williams, Fang Fang.   

Abstract

We have developed a technology for improving avidity by making bivalent, trivalent, or tetravalent recombinant polypeptides. We designed tripartite proteins consisting of the Fab fragment of an antibody fused with a hinge derived from human immunoglobulin D that was further linked to polymerization domains derived from human coiled-coil proteins. We report here on the application of this method with a Fab domain directed against the major human rhinovirus receptor, intercellular adhesion molecule 1 (ICAM-1). Multivalent anti-ICAM-1 molecules were produced in bacteria and purified as soluble preassembled homogeneous proteins at high yield. These proteins successfully blocked rhinovirus infection in vitro, with the efficiency increasing from monomer to dimer, trimer, and tetramer. The diminished dissociation rate of these multivalent antibodies and their improved efficacy in preventing rhinovirus infection provide a foundation for producing prophylactic and therapeutic molecules against human rhinovirus, the causative agent of the majority of common colds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12709314      PMCID: PMC153330          DOI: 10.1128/AAC.47.5.1503-1508.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

Review 1.  Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions.

Authors:  J Wen; T Arakawa; J S Philo
Journal:  Anal Biochem       Date:  1996-09-05       Impact factor: 3.365

Review 2.  New protein engineering approaches to multivalent and bispecific antibody fragments.

Authors:  A Plückthun; P Pack
Journal:  Immunotechnology       Date:  1997-06

Review 3.  Chemotherapy of rhinovirus colds.

Authors:  S J Sperber; F G Hayden
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

4.  Kinetics and thermodynamics of virus binding to receptor. Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance.

Authors:  J M Casasnovas; T A Springer
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

5.  A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants.

Authors:  P B Harbury; T Zhang; P S Kim; T Alber
Journal:  Science       Date:  1993-11-26       Impact factor: 47.728

6.  Nucleotide sequence of the gene for heat-stable enterotoxin II of Escherichia coli.

Authors:  R N Picken; A J Mazaitis; W K Maas; M Rey; H Heyneker
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

7.  The pUC plasmids, an M13mp7-derived system for insertion mutagenesis and sequencing with synthetic universal primers.

Authors:  J Vieira; J Messing
Journal:  Gene       Date:  1982-10       Impact factor: 3.688

8.  Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain Fv fragment-core streptavidin fusion.

Authors:  S M Kipriyanov; M Little; H Kropshofer; F Breitling; S Gotter; S Dübel
Journal:  Protein Eng       Date:  1996-02

9.  ATF-a0, a novel variant of the ATF/CREB transcription factor family, forms a dominant transcription inhibitor in ATF-a heterodimers.

Authors:  R Pescini; W Kaszubska; J Whelan; J F DeLamarter; R Hooft van Huijsduijnen
Journal:  J Biol Chem       Date:  1994-01-14       Impact factor: 5.157

10.  Development of an artificial antibody system with multiple valency using an Fv fragment fused to a fragment of protein A.

Authors:  W Ito; Y Kurosawa
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

View more
  7 in total

Review 1.  Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Authors:  Chuda Chittasupho; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  Ther Deliv       Date:  2011-07

2.  Adaptation of an ICAM-1-tropic enterovirus to the mouse respiratory tract.

Authors:  Eric S Wang; Elena Dobrikova; Christian Goetz; Andrew T Dufresne; Matthias Gromeier
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 3.  Host immune responses to rhinovirus: mechanisms in asthma.

Authors:  John T Kelly; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2008-10       Impact factor: 10.793

Review 4.  Biochemical prevention and treatment of viral infections - a new paradigm in medicine for infectious diseases.

Authors:  Hervé Le Calvez; Mang Yu; Fang Fang
Journal:  Virol J       Date:  2004-11-23       Impact factor: 4.099

Review 5.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

6.  ELISA-Based Assay for Studying Major and Minor Group Rhinovirus-Receptor Interactions.

Authors:  Petra Pazderova; Eva E Waltl; Verena Niederberger-Leppin; Sabine Flicker; Rudolf Valenta; Katarzyna Niespodziana
Journal:  Vaccines (Basel)       Date:  2020-06-18

Review 7.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.